{"disease":{"id":"aml-according-to-who-2016-classification-except-acute-promyelocytic-leukemia-and-refractory-to-induction-therapy-or-relapsed-after-first-line-treatment","name":"aml according to who 2016 classification except acute promyelocytic leukemia and refractory to induction therapy or relapsed after first line treatment"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03989713","title":"Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Prof. Dr. Richard F Schlenk","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}